Fate Therapeutics Cmn (FATE) 2.38 $FATE Fate Th
Post# of 273257
Posted On: 09/03/2016 11:18:57 AM
Fate Therapeutics Cmn (FATE) 2.38 $FATE
Fate Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Aug 31, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be presenting at two upcoming investor conferences in September:
FATE: 2.38 (-0.07), WFC: 50.55 (+0.12)
Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Wed Aug 10, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at the 2016 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 16, 2016 at 8:00 am ET.
FATE: 2.38 (-0.07)
Fate Therapeutics (FATE) Jumps: Stock Moves 22.8% Higher
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) shares rose almost 23% in the last trading session.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56)
Fate Therapeutics Reports Second Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 08, 3:01PM CDT
Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune(TM) for Prevention of Acute GvHD and CMV Infection
FATE: 2.38 (-0.07)
Fate Therapeutics Announces $10.3 Million Common Stock Private Placement
GlobeNewswire - Mon Aug 08, 7:00AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a securities purchase agreement for a private placement with a select group of institutional investors, including funds managed by Franklin Advisers, Inc., under which the investors have agreed to purchase 5,250,000 shares of the Company's common stock at a price of $1.96 per share, for gross proceeds of approximately $10.3 million. The Company expects to use the proceeds from the transaction primarily to advance its pipeline of programmed cellular immunotherapies and for general corporate purposes.
FATE: 2.38 (-0.07)
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2016 Financial Results on August 8, 2016
GlobeNewswire - Tue Aug 02, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, August 8, 2016 at 5:00 p.m. ET to report its second quarter 2016 financial results and provide a corporate update.
FATE: 2.38 (-0.07)
Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 2.38 (-0.07), ARNA: 1.57 (+0.01), EXEL: 11.54 (+0.19)
Geron (GERN) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:38AM CDT
With Geron (GERN) being a development stage company, investor focus will remain on imetelstat.
FATE: 2.38 (-0.07), JNJ: 119.32 (+0.24), GERN: 2.75 (+0.02), EXEL: 11.54 (+0.19)
Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) was a big mover last session, as its shares rose almost 6% on the day.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56)
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:25AM CDT
Fate Therapeutics, Inc. (FATE) moved big last session, as its shares jumped over 19% on the day.
FATE: 2.38 (-0.07), NEO: 8.00 (+0.05)
Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research
GlobeNewswire - Thu Jun 16, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled "Fighting Cancer with Off-the-Shelf iPSC Immunotherapies" at the 2016 Annual Meeting of the International Society for Stem Cell Research (ISSCR) on Wednesday, June 22, 2016 from 9:00 a.m. to 12:00 p.m. PT in San Francisco, California.
FATE: 2.38 (-0.07)
Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer
GlobeNewswire - Tue May 17, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer. Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization. As CMO, he will lead the design and execution of the Company's clinical trials for its programmed cellular immunotherapies.
FATE: 2.38 (-0.07)
Fate Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 4:12PM CDT
SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $8.4 million in its first quarter.
FATE: 2.38 (-0.07)
Fate Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 3:01PM CDT
Phase 1/2 Clinical Trial of ProTmune(TM) for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016
FATE: 2.38 (-0.07)
Tissue Engineering Market To Reach $11.53 Billion By 2022 Owing To Increased Focus Of Stem Cell Therapies: Grand View Research, Inc.
GlobeNewswire - Thu May 05, 4:00AM CDT
Global tissue engineering market is expected to reach USD 11.53 billion by 2022, according to a new report by Grand View Research, Inc. The demand for tissue engineering is expected to upsurge owing to the shift of focus from stem cell therapies to immunocelluar therapies. Moreover, companies such as Caladrius and Celyad changed their names from Cardio3 Bio NeoStem respectively to reflect their focus on immunotherapies.
FATE: 2.38 (-0.07)
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 9, 2016 at 5:00 p.m. ET to report its first quarter 2016 financial results and provide a corporate update.
FATE: 2.38 (-0.07)
Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) shares rose almost 7% in the last trading session.
FATE: 2.38 (-0.07), ANIK: 47.89 (-0.05)
Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Needham & Company 15th Annual Healthcare Conference in New York City on Tuesday, April 12, 2016 at 4:20 p.m. ET.
FATE: 2.38 (-0.07)
Vertex (VRTX) Down on CRL for Kalydeco Label Expansion
Arpita Dutt - Zacks Investment Research - Mon Feb 08, 4:38PM CST
The FDA informed Vertex (VRTX) that its sNDA for expanding the label of its CF treatment, Kalydeco, cannot be approved in its present form.
FATE: 2.38 (-0.07), VRTX: 95.11 (+0.36), LGND: 106.19 (-0.85), CELG: 105.49 (-0.88)
Fate Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Aug 31, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be presenting at two upcoming investor conferences in September:
FATE: 2.38 (-0.07), WFC: 50.55 (+0.12)
Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Wed Aug 10, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at the 2016 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 16, 2016 at 8:00 am ET.
FATE: 2.38 (-0.07)
Fate Therapeutics (FATE) Jumps: Stock Moves 22.8% Higher
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) shares rose almost 23% in the last trading session.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56)
Fate Therapeutics Reports Second Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 08, 3:01PM CDT
Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune(TM) for Prevention of Acute GvHD and CMV Infection
FATE: 2.38 (-0.07)
Fate Therapeutics Announces $10.3 Million Common Stock Private Placement
GlobeNewswire - Mon Aug 08, 7:00AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a securities purchase agreement for a private placement with a select group of institutional investors, including funds managed by Franklin Advisers, Inc., under which the investors have agreed to purchase 5,250,000 shares of the Company's common stock at a price of $1.96 per share, for gross proceeds of approximately $10.3 million. The Company expects to use the proceeds from the transaction primarily to advance its pipeline of programmed cellular immunotherapies and for general corporate purposes.
FATE: 2.38 (-0.07)
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2016 Financial Results on August 8, 2016
GlobeNewswire - Tue Aug 02, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, August 8, 2016 at 5:00 p.m. ET to report its second quarter 2016 financial results and provide a corporate update.
FATE: 2.38 (-0.07)
Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 2.38 (-0.07), ARNA: 1.57 (+0.01), EXEL: 11.54 (+0.19)
Geron (GERN) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:38AM CDT
With Geron (GERN) being a development stage company, investor focus will remain on imetelstat.
FATE: 2.38 (-0.07), JNJ: 119.32 (+0.24), GERN: 2.75 (+0.02), EXEL: 11.54 (+0.19)
Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) was a big mover last session, as its shares rose almost 6% on the day.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56)
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:25AM CDT
Fate Therapeutics, Inc. (FATE) moved big last session, as its shares jumped over 19% on the day.
FATE: 2.38 (-0.07), NEO: 8.00 (+0.05)
Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research
GlobeNewswire - Thu Jun 16, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled "Fighting Cancer with Off-the-Shelf iPSC Immunotherapies" at the 2016 Annual Meeting of the International Society for Stem Cell Research (ISSCR) on Wednesday, June 22, 2016 from 9:00 a.m. to 12:00 p.m. PT in San Francisco, California.
FATE: 2.38 (-0.07)
Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer
GlobeNewswire - Tue May 17, 7:01AM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer. Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization. As CMO, he will lead the design and execution of the Company's clinical trials for its programmed cellular immunotherapies.
FATE: 2.38 (-0.07)
Fate Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 4:12PM CDT
SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $8.4 million in its first quarter.
FATE: 2.38 (-0.07)
Fate Therapeutics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 3:01PM CDT
Phase 1/2 Clinical Trial of ProTmune(TM) for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016
FATE: 2.38 (-0.07)
Tissue Engineering Market To Reach $11.53 Billion By 2022 Owing To Increased Focus Of Stem Cell Therapies: Grand View Research, Inc.
GlobeNewswire - Thu May 05, 4:00AM CDT
Global tissue engineering market is expected to reach USD 11.53 billion by 2022, according to a new report by Grand View Research, Inc. The demand for tissue engineering is expected to upsurge owing to the shift of focus from stem cell therapies to immunocelluar therapies. Moreover, companies such as Caladrius and Celyad changed their names from Cardio3 Bio NeoStem respectively to reflect their focus on immunotherapies.
FATE: 2.38 (-0.07)
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Mon May 02, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 9, 2016 at 5:00 p.m. ET to report its first quarter 2016 financial results and provide a corporate update.
FATE: 2.38 (-0.07)
Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) shares rose almost 7% in the last trading session.
FATE: 2.38 (-0.07), ANIK: 47.89 (-0.05)
Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Needham & Company 15th Annual Healthcare Conference in New York City on Tuesday, April 12, 2016 at 4:20 p.m. ET.
FATE: 2.38 (-0.07)
Vertex (VRTX) Down on CRL for Kalydeco Label Expansion
Arpita Dutt - Zacks Investment Research - Mon Feb 08, 4:38PM CST
The FDA informed Vertex (VRTX) that its sNDA for expanding the label of its CF treatment, Kalydeco, cannot be approved in its present form.
FATE: 2.38 (-0.07), VRTX: 95.11 (+0.36), LGND: 106.19 (-0.85), CELG: 105.49 (-0.88)
(0)
(0)Scroll down for more posts ▼